Treatment of Zoon Plasma Cell Vulvitis
High-potency topical corticosteroids, specifically clobetasol 0.05% ointment, should be used as first-line therapy for Zoon plasma cell vulvitis, with tacrolimus 0.1% ointment as an alternative if corticosteroids fail or are not tolerated 1, 2.
Clinical Context and Diagnosis
Plasma cell vulvitis (PCV) is a rare chronic inflammatory condition affecting approximately 0.28% of women presenting to vulvar clinics 3. The condition typically presents with:
- Burning/stinging sensation (52% of cases) - the most common symptom
- Dyspareunia (44%)
- Pruritus (41%)
- Characteristic erythematous, glistening/shiny lesions (84% show erythema, 29% have glistening appearance)
- Well-demarcated plaques or macules (25%)
- Most commonly affects labia minora (45%), introitus (31%), and periurethral areas (19%) 1
The diagnosis requires histopathologic confirmation showing predominant plasma cell infiltrate (88%), often with hemosiderin deposits (46%) and epidermal atrophy (43%) 1.
Treatment Algorithm
First-Line Therapy
Clobetasol 0.05% ointment applied to affected areas once or twice daily is the most evidence-supported treatment 1, 2, 3. This recommendation is based on:
- Most frequently used treatment modality (64% of reported cases) 1
- Identified as the preferred treatment in long-term follow-up studies 3
- Consistent with management principles for other inflammatory vulvar conditions 4
Application approach:
- Apply thin layer to affected areas once or twice daily initially
- Taper frequency as symptoms improve
- Many patients require long-term maintenance therapy given the chronic nature of the condition 3
Second-Line Therapy
Tacrolimus 0.1% ointment should be considered when:
- Corticosteroids are ineffective after 4-6 weeks of appropriate use
- Local side effects from prolonged corticosteroid use develop
- Patient preference for non-steroidal therapy
Tacrolimus was used in 13% of reported cases 1, though evidence is more limited than for corticosteroids. Important caveat: Patients should be warned about potential stinging/burning on application, which is common with calcineurin inhibitors 4.
Third-Line Options
If both topical corticosteroids and tacrolimus fail:
Topical imiquimod - has limited supporting evidence but has been used successfully in refractory cases 2
Surgical excision - reserved for localized, refractory lesions that have failed medical management 2
Platelet-rich plasma therapy - emerging novel treatment with case report evidence showing improvement in recalcitrant cases 5
Avoid cryotherapy - this has the least supporting evidence and should not be used 2.
Critical Management Considerations
Diagnostic Delay is Common
Most patients have tried multiple treatments before correct diagnosis 1. The condition is frequently misdiagnosed as:
- Vulvovaginal candidiasis (note: the provided candidiasis guidelines 6, 7, 8, 9, 8 are not relevant to PCV treatment)
- Lichen planus
- Genitourinary syndrome of menopause 10
Long-Term Follow-Up Required
At median 5-year follow-up, more than half of patients remain symptomatic with moderate to large impact on quality of life 3. This necessitates:
- Long-term support and monitoring
- Realistic expectations about chronicity
- Maintenance therapy planning
Treatment Response Variability
While some patients achieve complete symptom resolution, many require ongoing treatment. Symptoms are often precipitated by friction and sexual activity 3.
Quality of Life Impact
The condition significantly affects sexual function and daily activities, warranting aggressive initial treatment and sustained management 2, 3.
Practical Implementation
Start with: Clobetasol 0.05% ointment applied once daily to affected areas for 4-6 weeks
If partial response: Continue clobetasol but may increase to twice daily application
If no response after 6 weeks: Switch to tacrolimus 0.1% ointment twice daily (warn about initial stinging)
If refractory to both: Consider referral to vulvar specialist for consideration of imiquimod, surgical excision, or emerging therapies like platelet-rich plasma
For maintenance: Taper successful therapy to lowest effective frequency rather than discontinuing completely, as recurrence is common
The evidence base consists primarily of case reports and case series 1, 2, with no randomized controlled trials available. However, the consistent use and reported efficacy of high-potency topical corticosteroids across multiple studies supports their use as first-line therapy.